Adventrx: FDA Rejects Lung Cancer Drug
The setback raises serious and legitimate questions about Adventrx's qualifications as a drug developer and should pop the speculative trading bubble that's over-inflated the company's valuation all summer.
Adventrx shares closed Tuesday at $2.54 ahead the announcement of the Exelbine rejection. The company isn't worth more than the cash on its books -- $40 million, or about $1.11 a share. For its sheer stupidity and the fact that Adventrx still intends to spend (waste) its cash, the stock should trade below cash value.
That's because Adventrx appears to lack any ability to get even the simplest of drugs approved by the U.S. Food and Drug Administration. Exelbine is a proprietary reformulation of the chemotherapy drug vinorelbine -- nothing fancy or complicated about it. The only requirement to get Exelbine approved was to show in a very straightforward and small study that Exelbine was biologically equivalent to vinorelbine.Yet somehow, Adventrx managed to screw up this simple task. Unbelievable. Based on inspections of clinical trial sites, FDA reviewers were unable to verify the "authenticity" of the drugs used in the bioequivalence study, which put the results of the study in question, according to Adventrx's explanation of the FDA rejection letter. Step back a moment and think about what that means: FDA is accusing Adventrx of running a clinical study so mismanaged that determining which lung cancer patients received either Exelbine or vinorelbine could not be determined. Doh! If that's not enough, FDA still has unanswered questions about the quality and manufacturing of Exelbine, according to Adventrx. Yet these were concerns that Adventrx was supposed to have assuaged after FDA issued refuse-to-file letter for Exelbine in March 2010. In July, I argued that Adventrx -- trading near $4 a share at the time -- was wildly over-valued based on the tiny commercial opportunity for Exelbine. I assumed Adventrx would manage to get Exelbine approved, even though the drug would barely generate any revenue. I was right about the stock for the wrong reasons. I gave Adventrx too much credit. I didn't believe the company could be as incompetent as it's now proven to be.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV